T Cell Engager Formats Patents: Who Leads, Trends 2026
T Cell Engager Formats: Patents Shaping CD3-Directed Bispecifics
Concentrated but not closed. the leading assignee holds 703 records and the top 5 combine for 27.7% of all 8,408 records in scope — a strong core with room outside it. Filings rose from 496 in 2017 to a peak of 993 in 2023, then held roughly flat through 2024 (973 to 979, +1%) before the 2025–2026 figures — still incomplete under the publication lag — taper toward 119. Read the plateau, not the tail, as the current signal.
- 1JANSSEN BIOTECH INC8.4%
- 2F HOFFMANN LA ROCHE & CO AG7.8%
- 3REGENERON PHARMACEUTICALS INC3.9%
- 4AMGEN INC3.8%
- 5NOVARTIS AG3.7%
See the full t cell engager formats analysis in Eureka
- The complete ranking, not just the top five
- Every IPC branch with its share of the corpus
- The most-cited records, and where claim space is still thin
Common questions on T cell engager format patents
Who holds the most patents on T cell engager formats?
The dataset’s ranked leader holds 703 of the 8,408 records in scope, with the top 5 assignees combined accounting for 27.7% of all records. That concentration sits alongside a long tail of smaller filers, so cumulative leadership does not mean the field is closed — plenty of assignees hold single-digit filing counts in specific sub-areas. Anyone assessing competitive position should look at both the cumulative ranking and the recent-year momentum, since the two often diverge.
Is filing activity in T cell engager formats still growing?
Filing volume rose steadily to a peak of 993 in 2023, and the 2021-to-2024 span (the last year treatable as complete) shows essentially flat growth at +1%. The apparent decline in 2025 and 2026 figures is an artefact of the roughly 18-month lag between filing and publication, not a genuine drop in activity. Treat any trend line’s final one to two years as provisional rather than a signal of slowing interest.
What technical areas are least covered by existing patents?
Relative to the dominant C07K (84.3% of records) and A61K (68.1%) classes covering the engager molecules and their formulations, classes tied to analytical methods (G01N, 4.2%), enzymatic synthesis (C12P, 1.1%), and diagnostic measurement (C12Q, 0.9%) carry far fewer filings. That gap suggests assay-based and manufacturing-process claims around T cell engagers are comparatively under-claimed relative to the core molecule architectures they support.
Disclaimer. This analysis is based on Patsnap Eureka data drawn from a limited snapshot of global patent records and is provided for general information and reference only. Patent data carries inherent limitations — recent filings are under-counted because of publication lag, counts may be on a record or family basis, classification and applicant-name data may contain errors or duplicates, and the underlying search query defines the scope shown — so the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing here is an exhaustive prior-art, novelty, freedom-to-operate or validity search, nor does it constitute legal, financial or professional advice, and it should not be relied upon as such. Verify independently and review with qualified patent and legal professionals before acting on it.
Method: Filing trend and technology composition. Derived from a Patsnap search on T Cell Engager Formats covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish. Every share divides by all records in scope. Data: Patsnap Eureka. See the full landscape report.